Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039702 · ClinicalTrials.gov registry record
Brain Imaging in Alzheimer's Disease
A clinical trial of Alzheimer Disease, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT00039702 is a study of Alzheimer Disease that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 40 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00039702, a study of Alzheimer Disease, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to use brain imaging technology to examine the role of certain brain chemicals in individuals with Alzheimer's disease (AD) and in healthy volunteers. Cognitive dysfunction in people with AD is thought to arise from decreased chemical activity in specific parts of the brain. Decreases in alpha4beta2 nicotinic acetycholine receptors (nAChRs) have been found in the brains of people who died with AD; however, the status of this receptor system in living brains remains unclear. This study will use single photon emission computed tomography (SPECT) to study this receptor system in people with AD who have mild to moderate dementia and in healthy volunteers. In addition, this study will examine the relationship between cognitive dysfunction and nAChR deficits in the brains of individuals with AD. Participants with AD will have four clinic visits; healthy volunteers will have three visits. At Visit 1, participants will undergo a medical history, physical examination, and laboratory tests. Healthy volunteers will have a Mini-Mental State Examination (MMSE) cognitive function test. Participants with AD will have a MMSE and measurement of the severity of their dementia. During Visit 2, participants will undergo a magnetic resonance imaging (MRI) scan of the brain. At Visit 3, participants will undergo SPECT imaging. Only participants with AD will participate in Visit 4. During this visit, cognitive testing will be performed.
Conditions Studied
Interventions
- DRUG [123] 5-I-A-85380
Study Locations (1)
Maryland
- National Institute of Mental Health (NIMH) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039702
The ClinicalTrials.gov registry entry for NCT00039702 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [123] 5-I-A-85380 is the first listed.
NCT00039702 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00039702 about?
NCT00039702 is a clinical study titled "Brain Imaging in Alzheimer's Disease". The purpose of this study is to use brain imaging technology to examine the role of certain brain chemicals in individuals with Alzheimer's disease (AD) and in healthy volunteers. Cognitive dysfunction in people with AD is thought to arise from decreased chemical activity in specific parts of the b...
What is the current status of trial NCT00039702?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2002-06. Estimated completion is 2004-09.
What conditions does trial NCT00039702 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT00039702?
The interventions under investigation include: [123] 5-I-A-85380 (DRUG).
Who is sponsoring clinical trial NCT00039702?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00039702 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.